Changes in Hong Kong stocks | Laikai Pharmaceutical-B (02105) rose more than 5% in early trading LAE002 is expected to submit an NDA in the first half of '26

The Zhitong Finance App learned that Laikai Pharmaceutical-B (02105) rose more than 5% in early trading. As of press release, it had risen 5.63% to HK$16.9, with a turnover of HK$28.6972 million.

According to the news, Laikai Pharmaceutical previously signed an exclusive agreement with Qilu Pharmaceutical to license Qilu Pharmaceutical to conduct research, development and commercialization of LAE002 in China. The company is responsible for completing the HR+/HER2-breast cancer phase III clinical trial until the first indication is approved in China. It is entitled to a non-refundable down payment and clinical development milestone payment of up to RMB 540 million, and can receive up to RMB 2,045 billion in down payments and milestone payments, and can also receive a gradient sales share of more than 10 to 20 percentage points of future net sales within the licensed region.

Yongxing Securities released a research report stating that LAE002 is expected to submit an NDA in the first half of '26. The company's pipeline progressed smoothly. LAE002 was authorized to Qilu. LAE102's MAD data is excellent, and LAE103's IND application has been approved by the FDA; the bank used the DCF valuation method for LAE102, covering it for the first time, giving the company a “buy” rating.